S&P 500
7,718.60
-29.11
-0.38%
Dow
53,414.25
-271.85
-0.51%
Nasdaq
26,506.99
-77.11
-0.29%
NYSE Composite
24,639.25
-80.95
-0.33%
Russell 2000
2,975.65
+7.38
+0.25%
VIX
15.30
+0.77
+5.30%
TARS · Tarsus Pharmaceuticals, Inc.
NASDAQ NMS - GLOBAL MARKET - Real Time Price • USD
Tarsus Pharmaceuticals Inc (TARS)
NASDAQ NMS - GLOBAL MARKET
Pharmaceuticals
$90.89
+7.76
(+9.33%)
● Market open
DAY'S RANGE
$90.89
$82.36
$91.44
52-WEEK RANGE
$90.89
$48.20
$91.53
What's happening
- TARS is up 9.33% today, trading at $90.89. — Live quote
- It's trading within 3% of its 52-week high ($91.53). (Finnhub fundamentals)
- Volume today (111,462) is well below its 3-month average of 914,080. (Finnhub fundamentals)
- Last quarter's EPS missed estimates: $-0.49 actual vs. $-0.20 estimated (-145.1%). (Finnhub earnings history)
Deterministic template sentences filled in from the same sourced figures shown elsewhere on this page -- not an AI-written summary, no live model call.
Key Statistics
Analyst Recommendations
Strong buy 7
Buy 6
Hold 1
Sell 0
Strong sell 0
Aggregate ratings for 2026-09-01 (14 analysts polled by Finnhub) — consensus count.
Performance Overview (Trailing returns vs S&P 500 benchmark)
YTD RETURN
TARS
+10.87%
vs S&P 500
-2.07%
1-YEAR RETURN
TARS
+57.52%
vs S&P 500
+38.53%
6-MONTH RETURN
TARS
+18.59%
3-MONTH RETURN
TARS
+50.45%
Earnings Trends (Quarterly EPS Actual vs Estimate)
2026-07-26 (Q2 2026)
$-0.49
Est. $-0.20
MISS -145.1%
2026-04-26 (Q1 2026)
$-0.16
Est. $-0.38
BEAT +57.6%
2026-01-26 (Q4 2025)
$-0.20
Est. $-0.10
MISS -106.2%
2025-10-26 (Q3 2025)
$-0.30
Est. $-0.36
BEAT +16.1%
Valuation Measures & Ratios
Enterprise Value4$3.85B
Forward P/E540.86
PEG Ratio6—
Price / Sales (TTM1)6.57
Price / Book77.81
EV4 / Revenue6.35
EV4 / EBITDA—
Profit Margin-7.67%
Operating Margin-8.00%
Return on Equity (ROE8)-13.53%
Return on Assets (ROA9)-8.12%
Avg Volume (3M)914,080
Quarterly history (5 periods)
| Measure | Jun '26 | Mar '26 | Sep '25 | Jun '25 | Mar '25 |
|---|---|---|---|---|---|
| Market cap | $2.72B | $3.05B | $2.49B | $1.72B | $2.01B |
| P/E | -46.49 | -46.93 | -30.62 | -16.81 | -17.13 |
| Price/Sales | 4.87 | 6.61 | 7.17 | 6.36 | 10.34 |
| Price/Book | 7.84 | 8.74 | 7.45 | 5.16 | 5.88 |
| EV/Revenue | 4.64 | 6.54 | 7.06 | 6.27 | 9.80 |
| ROE | -16.86% | -18.63% | -24.31% | -30.72% | -34.33% |
| ROA | -9.56% | -11.19% | -15.24% | -20.64% | -23.48% |
Trailing-twelve-month ratios computed from SEC EDGAR quarterly figures and historical daily close prices (Alpaca). Diluted shares are derived from Net income ÷ EPS (diluted) for each quarter, not separately reported. Forward P/E and PEG aren't shown here — both need historical analyst-consensus estimates, which no free source provides; see the current-period figures above instead.
Glossary — what these abbreviations mean
- 1. TTM
- Trailing twelve months — the sum of the last four reported quarters, not a calendar year or the single latest quarter.
- 2. EPS
- Earnings per share — net income divided by diluted shares outstanding.
- 3. Beta
- A stock's historical volatility relative to the overall market. Above 1 means it has moved more than the market; below 1, less.
- 4. EV (Enterprise Value)
- Market cap plus total debt minus cash — roughly what it would cost to buy the whole company, debt included.
- 5. Forward P/E
- Price divided by analysts' estimated earnings for the next 12 months, instead of trailing actual earnings.
- 6. PEG Ratio
- P/E divided by expected earnings growth rate. A lower number can indicate a stock is cheap relative to how fast it's expected to grow.
- 7. Price / Book
- Share price divided by book value (assets minus liabilities) per share.
- 8. ROE
- Return on equity — net income divided by shareholders' equity, a measure of how efficiently a company turns equity into profit.
- 9. ROA
- Return on assets — net income divided by total assets, a measure of how efficiently a company turns assets into profit.
- 10. MRQ
- Most recent quarter — the single latest reported period, as opposed to TTM. The Financials section's "Quarterly" view below shows MRQ-style figures.
- 11. YoY
- Year over year — percent change versus the same period one year earlier, used for growth figures like those on Compare cards and the Screener.
Short Interest
Shares Short5,997,475
Change from Prior Settlement-0.32%
% of Float—
Days to Cover (Short Ratio)7.49
Source: FINRA Rule 4560 consolidated short interest, settlement date 2026-08-14. Reported bi-monthly with a reporting lag — not real-time.
Quotes and the 1-day extended-hours chart: Yahoo Finance. Longer historical charts: Alpaca (IEX feed) — real-time but IEX-only volume (~2.5% of consolidated market volume). Fundamentals + earnings: Finnhub.
Price history
Events
Drag horizontally to zoom into a section; use Reset view to restore all observations.
Technical signal summary
Calculating from the latest year of daily price history…
Show Technical Analysis Breakdown ▾ 10 Indicators
Signals describe daily price patterns—not the company’s value and not a recommendation to buy or sell. Read several together; no single indicator predicts what happens next. “Overbought” and “oversold” are conditions, not promises of a reversal.
Indicators None active
Loading chart…
Free IEX historical data only goes back to ~2021 — 5Y/Full show whatever's actually available, not a promise of that much history. Indicators are computed client-side from these same price bars; earnings markers ("E") come from Finnhub's free tier (~last 4 quarters + next upcoming) — older quarters aren't available. The move-highlight dots are a heuristic (|% change| vs rolling volatility) with a best-effort headline lookup, not a claim of causation.
Peer and sector context
No reviewed peer group is available for this symbol.
Balanced evidence
A deterministic summary of sourced facts—not an AI verdict.
Potential strengths
- Revenue growth is 69.4% on the provider's reported measure. Finnhub fundamentals ↗
- Trailing 52-week price return is +57.5%. Finnhub market metrics ↗
Potential concerns
- Net profit margin is -7.7%. Finnhub fundamentals ↗
- Latest SEC filing is Form 4, filed 2026-09-03; review it for current changes and risks. SEC EDGAR ↗
Rule-based facts only; absence from either side is not evidence, and this is not a recommendation.
More on TARS
No accessible free API for these — links go to the source directly.
Financials
Fundamental trends
Visualized from the same SEC figures in the tables below.
Income statement
| Line item | Jun '26 | Mar '26 | Sep '25 | Jun '25 | Mar '25 | Sep '24 | Jun '24 | Mar '24 |
|---|---|---|---|---|---|---|---|---|
| Revenue | $173.9M | $162.1M | $118.7M | $102.7M | $78.3M | $48.1M | $40.8M | $27.6M |
| Operating income | -$19.9M | -$6.1M | -$14.5M | -$22.2M | -$26.3M | -$25.2M | -$33.3M | -$37.7M |
| Net income | -$18.6M | -$7.0M | -$12.6M | -$20.3M | -$25.1M | -$23.4M | -$33.3M | -$35.7M |
| EPS (diluted) | $-0.43 | $-0.16 | $-0.30 | $-0.48 | $-0.64 | $-0.61 | $-0.88 | $-1.01 |
| EPS (basic) | $-0.43 | $-0.16 | $-0.30 | $-0.48 | $-0.64 | $-0.61 | $-0.88 | $-1.01 |
| Operating margin | -$11 | -$4 | -$12 | -$22 | -$34 | -$52 | -$82 | -$136 |
| Net margin | -$11 | -$4 | -$11 | -$20 | -$32 | -$49 | -$82 | -$129 |
Balance sheet
| Line item | Jun '26 | Mar '26 | Dec '25 | Sep '25 | Jun '25 | Mar '25 | Dec '24 | Sep '24 |
|---|---|---|---|---|---|---|---|---|
| Total assets | $611.1M | $581.1M | $562.2M | $534.6M | $495.0M | $500.8M | $377.0M | $376.3M |
| Total liabilities | $264.4M | $232.2M | $218.7M | $199.5M | $162.4M | $158.3M | $152.5M | $138.8M |
| Stockholders' equity | $346.7M | $349.0M | $343.4M | $335.1M | $332.6M | $342.5M | $224.5M | $237.5M |
| Total current assets | $562.0M | $537.2M | $522.8M | $501.7M | $474.4M | $480.8M | $356.7M | $357.1M |
| Total current liabilities | $175.8M | $143.5M | $135.7M | $117.0M | $90.3M | $86.3M | $80.6M | $65.9M |
| Cash & equivalents | $204.6M | $102.2M | $183.6M | $112.7M | $96.6M | $175.8M | $94.8M | $176.2M |
| Marketable securities (current) | $245.1M | $286.5M | $233.6M | $289.1M | $284.5M | $232.1M | $196.6M | $140.7M |
| Accounts receivable | $96.0M | $100.3M | $85.1M | $72.6M | $58.3M | $62.4M | $46.8M | $29.2M |
| Inventory | $4.4M | $4.6M | $4.4M | $3.8M | $3.9M | $2.7M | $2.6M | $2.8M |
| Other current assets | — | — | — | — | — | — | — | — |
| Marketable securities (non-current) | $6.7M | $3.9M | $3.9M | $3.0M | $3.0M | $3.0M | $3.0M | $3.0M |
| Property, plant & equipment | $20.5M | $17.7M | $11.7M | $5.7M | $3.2M | $2.8M | $2.3M | $2.4M |
| Intangible assets | $6.9M | $7.1M | $7.4M | $7.6M | $7.8M | $8.1M | $8.3M | $8.6M |
| Other non-current assets | $660.0K | $715.0K | $1.9M | $1.2M | $1.2M | $616.0K | $999.0K | $888.0K |
| Accounts payable | $40.1M | $24.1M | $16.4M | — | — | — | $9.4M | — |
| Deferred revenue (current) | — | — | — | — | — | — | — | — |
| Other current liabilities | $25.4M | $32.5M | $22.2M | — | — | — | $18.3M | — |
| Long-term debt | $72.8M | $72.6M | $72.4M | $72.3M | $72.1M | $72.0M | $71.8M | $71.7M |
| Other non-current liabilities | $15.9M | $16.1M | $10.6M | $10.1M | — | — | $0 | $1.2M |
| Common stock & paid-in capital | $6.0K | $6.0K | $6.0K | $6.0K | $6.0K | $6.0K | $6.0K | $6.0K |
| Retained earnings | -$452.1M | -$433.6M | -$426.6M | -$418.3M | -$405.7M | -$385.3M | -$360.2M | -$337.1M |
| Accumulated other comprehensive income (loss) | -$557.0K | -$298.0K | $381.0K | $289.0K | $39.0K | $85.0K | $179.0K | $346.0K |
Cash flow
| Line item | Jun '26 | Mar '26 | Dec '25 | Sep '25 | Jun '25 | Mar '25 | Dec '24 | Sep '24 |
|---|---|---|---|---|---|---|---|---|
| Operating cash flow | $61.2M | -$24.7M | $19.3M | $18.3M | -$29.4M | -$20.7M | -$22.2M | -$8.7M |
| Investing cash flow | $37.9M | -$58.6M | $49.3M | -$4.7M | -$51.7M | -$34.9M | -$59.6M | $3.1M |
| Financing cash flow | $3.3M | $1.2M | $2.3M | $2.6M | $2.0M | $136.6M | $2.9M | $639.0K |
| Free cash flow | $57.2M | -$30.5M | $13.0M | $16.3M | -$30.4M | -$21.2M | -$22.3M | -$8.9M |
| Capital expenditures | $4.1M | $5.8M | $6.4M | $1.9M | $1.0M | $590.0K | $72.0K | $282.0K |
| Share-based compensation | $13.3M | $12.0M | $14.3M | $12.2M | $8.2M | $6.9M | $7.4M | $7.4M |
| Deferred income taxes | — | — | $0 | — | — | — | $0 | — |
| Change in accounts receivable | -$19.3M | $30.3M | $12.4M | $14.3M | -$4.1M | $15.7M | $17.6M | -$370.0K |
| Change in inventory | -$198.0K | $196.0K | $536.0K | -$37.0K | $1.2M | $84.0K | -$227.0K | $652.0K |
| Purchases of investments | $2.4M | $126.8M | $35.6M | $102.3M | $129.7M | $125.6M | $90.0M | $21.1M |
| Sales/maturities of investments | — | — | — | — | — | — | — | $24.5M |
| Debt issued | — | — | $0 | $0 | $0 | — | $0 | $0 |
Income statement
| Line item | Dec '25 | Dec '24 | Dec '23 | Dec '22 | Dec '21 |
|---|---|---|---|---|---|
| Revenue | $451.4M | $183.0M | $17.4M | $25.8M | $57.0M |
| Operating income | -$71.0M | -$120.6M | -$143.2M | -$62.7M | -$12.2M |
| Net income | -$66.4M | -$115.6M | -$135.9M | -$62.1M | -$13.8M |
| EPS (diluted) | $-1.59 | $-3.07 | $-4.62 | $-2.52 | $-0.67 |
| EPS (basic) | $-1.59 | $-3.07 | $-4.62 | $-2.52 | $-0.67 |
| Operating margin | -$16 | -$66 | -$821 | -$243 | -$21 |
| Net margin | -$15 | -$63 | -$779 | -$241 | -$24 |
Balance sheet
| Line item | Dec '25 | Dec '24 | Dec '23 | Dec '22 | Dec '21 |
|---|---|---|---|---|---|
| Total assets | $562.2M | $377.0M | $265.5M | $227.9M | $178.9M |
| Total liabilities | $218.7M | $152.5M | $68.5M | $35.0M | $12.2M |
| Stockholders' equity | $343.4M | $224.5M | $197.0M | $192.9M | $166.7M |
| Total current assets | $522.8M | $356.7M | $256.1M | $225.4M | $176.0M |
| Total current liabilities | $135.7M | $80.6M | $36.9M | $15.4M | $11.5M |
| Cash & equivalents | $183.6M | $94.8M | $224.9M | $71.7M | $171.3M |
| Marketable securities (current) | $233.6M | $196.6M | $2.5M | $145.4M | $483.0K |
| Accounts receivable | $85.1M | $46.8M | $16.6M | $0 | — |
| Inventory | $4.4M | $2.6M | $3.1M | $0 | — |
| Marketable securities (non-current) | $3.9M | $3.0M | $631.0K | $371.0K | $0 |
| Property, plant & equipment | $11.7M | $2.3M | $1.5M | $957.0K | $755.0K |
| Intangible assets | $7.4M | $8.3M | $3.9M | $0 | — |
| Other non-current assets | $1.9M | $999.0K | $1.5M | $585.0K | $1.1M |
| Accounts payable | $16.4M | $9.4M | — | — | — |
| Deferred revenue (current) | — | — | — | $0 | $697.0K |
| Other current liabilities | $22.2M | $18.3M | — | — | — |
| Long-term debt | $72.4M | $71.8M | $29.8M | $19.4M | $0 |
| Other non-current liabilities | $10.6M | $0 | $1.7M | $100.0K | $699.0K |
| Common stock & paid-in capital | $6.0K | $6.0K | $5.0K | $5.0K | $4.0K |
| Retained earnings | -$426.6M | -$360.2M | -$244.7M | -$108.8M | -$46.7M |
| Accumulated other comprehensive income (loss) | $381.0K | $179.0K | -$2.0K | -$74.0K | $0 |
Cash flow
| Line item | Dec '25 | Dec '24 | Dec '23 | Dec '22 | Dec '21 |
|---|---|---|---|---|---|
| Operating cash flow | -$12.5M | -$83.0M | -$117.5M | -$49.0M | $3.7M |
| Investing cash flow | -$42.1M | -$199.2M | $140.6M | -$144.6M | -$586.0K |
| Financing cash flow | $143.4M | $154.7M | $130.2M | $94.0M | $21.0K |
| Free cash flow | -$22.3M | -$84.6M | -$119.0M | -$49.5M | $3.2M |
| Capital expenditures | $9.9M | $1.6M | $1.5M | $506.0K | $586.0K |
| Share-based compensation | $41.7M | $27.8M | $19.8M | $13.5M | $8.5M |
| Deferred income taxes | $0 | $0 | $0 | $0 | $0 |
| Change in accounts receivable | $38.3M | $30.1M | $16.6M | $0 | — |
| Change in inventory | $1.8M | $2.0M | $3.1M | $0 | — |
| Purchases of investments | $393.2M | $262.6M | $28.7M | $149.4M | $0 |
| Debt issued | $0 | $75.0M | $10.0M | $20.0M | — |
Source: SEC EDGAR XBRL filings (10-Q/10-K), as originally tagged by the company. Quarterly cash flow is reconstructed by de-cumulating fiscal-year-to-date figures (how cash flow is tagged in 10-Qs); other quarterly lines are reported directly.
Institutional holders
SEC Form 13F filers holding TARS as of the latest reported quarter. 13F only covers investment managers with $100M+ in assets — this is not a complete ownership picture, and does not include insiders (see Recent SEC filings below) or non-13F-eligible holders.
Source: Business Quant SEC Form 13F · report period 2026-06-30 · 30 filers
Held by These Filers88.1%
Shares Outstanding43,393,643
| Filer | Shares | Value | % Out | Qtr Change | Filed |
|---|---|---|---|---|---|
| BlackRock, Inc. | 3,856,137 | $242.7M | 8.89% | +8.5% | 2026-08-07 |
| Deep Track Capital, LP | 3,666,768 | $230.8M | 8.45% | +1.9% | 2026-08-14 |
| RTW INVESTMENTS, LP | 3,357,059 | $211.3M | 7.74% | +0.3% | 2026-08-14 |
| Jupiter Topco LLC | 2,808,796 | $176.8M | 6.47% | +0.0% | 2026-08-14 |
| Paradigm Biocapital Advisors LP | 2,775,649 | $174.7M | 6.40% | +8.3% | 2026-08-14 |
| Morgan Stanley | 1,827,082 | $115.0M | 4.21% | -6.0% | 2026-08-11 |
| VANGUARD CAPITAL MANAGEMENT LLC | 1,793,064 | $112.9M | 4.13% | +1.8% | 2026-06-30 |
| JENNISON ASSOCIATES LLC | 1,663,655 | $104.7M | 3.83% | -2.8% | 2026-08-03 |
| TANG CAPITAL MANAGEMENT LLC | 1,568,266 | $98.7M | 3.61% | +31.9% | 2026-08-14 |
| MILLENNIUM MANAGEMENT LLC | 1,427,124 | $89.8M | 3.29% | +152.8% | 2026-08-14 |
| Bank Of America Corp /De/ | 1,193,182 | $75.1M | 2.75% | -0.1% | 2026-08-14 |
| GEODE CAPITAL MANAGEMENT, LLC | 1,105,689 | $69.6M | 2.55% | -1.4% | 2026-08-12 |
| State Street Corp | 1,072,951 | $67.5M | 2.47% | +9.7% | 2026-08-07 |
| Vestal Point Capital, LP | 1,050,000 | $66.1M | 2.42% | +425.0% | 2026-08-14 |
| Assenagon Asset Management S.A. | 947,495 | $59.6M | 2.18% | -26.0% | 2026-07-08 |
| Invesco Ltd. | 785,808 | $49.5M | 1.81% | +5.8% | 2026-08-13 |
| Goldman Sachs Group Inc | 742,693 | $46.7M | 1.71% | +68.9% | 2026-08-14 |
| Frazier Life Sciences Management, L.P. | 728,644 | $45.9M | 1.68% | +0.0% | 2026-08-14 |
| D. E. Shaw & Co., Inc. | 710,559 | $44.7M | 1.64% | -10.2% | 2026-08-14 |
| FMR LLC | 672,949 | $42.4M | 1.55% | -8.2% | 2026-08-13 |
| NOMURA ASSET MANAGEMENT INTERNATIONAL INC. | 607,272 | $38.2M | 1.40% | +21.5% | 2026-08-14 |
| Clearbridge Investments, LLC | 549,387 | $34.6M | 1.27% | +0.7% | 2026-08-10 |
| Toronto Dominion Bank | 510,253 | $32.1M | 1.18% | +0.0% | 2026-08-14 |
| LORD, ABBETT & CO. LLC | 479,266 | $30.2K | 1.10% | -43.1% | 2026-08-13 |
| MASSACHUSETTS FINANCIAL SERVICES CO /MA/ | 427,008 | $26.9M | 0.98% | +0.0% | 2026-08-03 |
Insider activity
Directors, officers, and 10%+ owners' reported transactions from SEC Form 4. A filing reports a transaction; it does not by itself explain why it happened.
Source: SEC EDGAR Form 4 filings · checked 25 most recent filings · covers 2026-03-17 to 2026-09-02
Recent transactions
- Insiders have net sold 113,511 shares over the last 182 days, across 0 purchases and 23 sales.
- Most recent: Azamian Bobak R. (President/CEO and Board Chair) — Open market sale of 10,000 shares on 2026-09-02.
Deterministic template sentences filled in from the SEC Form 4 figures in the tables below -- not an AI-written summary, no live model call.
Insider purchases & sales, last 6 months
Purchases (open market)0 sh(0 txns)
Sales (open market)113,511 sh(23 txns)
Net Shares-113,511
Counts only open-market purchases (code P) and sales (code S) — grants, option exercises, tax withholding, and gifts are excluded since they aren't a market buy/sell decision.
Insider roster
| Name | Title | Most Recent Transaction | Date | Shares |
|---|---|---|---|---|
| Azamian Bobak R. | President/CEO and Board Chair | Open market sale | 2026-09-02 | 10,000 |
| Lin Elizabeth Yeu | Chief Medical Officer | Open market sale | 2026-09-02 | 5,387 |
| Farrow Jeffrey S | See Remarks | Open market sale | 2026-06-16 | 14,396 |
| Goodrich Katherine | Director | Open market sale | 2026-06-15 | 2,954 |
| LINK WILLIAM J PHD | Director | Open market sale | 2026-06-15 | 10,572 |
| Morrison Scott W | Director | Option exercise | 2026-06-12 | 2,954 |
| CHAUDHURI BHASKAR | Director | Option exercise | 2026-06-12 | 2,954 |
| YARNO WENDY L | Director | Option exercise | 2026-06-12 | 2,954 |
| Goldberg Andrew D. | Director | Option exercise | 2026-06-12 | 2,954 |
| PYOTT DAVID E I | Director | Option exercise | 2026-04-24 | 1,383 |
| Neervannan Seshadri | Chief Operating Officer | Open market sale | 2026-03-20 | 2,989 |
| Whitfield Dianne C. | Chief Human Resources Officer | Open market sale | 2026-03-19 | 4,174 |
| Wahl Bryan | General Counsel | Open market sale | 2026-03-19 | 4,231 |
| Mottiwala Aziz | Chief Commercial Officer | Open market sale | 2026-03-19 | 4,440 |
Recent transactions
| Date | Insider | Title | Transaction | Shares | Price |
|---|---|---|---|---|---|
| 2026-09-02 | Azamian Bobak R. | President/CEO and Board Chair | Open market sale | 10,000 | $80.06 |
| 2026-09-02 | Lin Elizabeth Yeu | Chief Medical Officer | Open market sale | 5,387 | $80.00 |
| 2026-09-02 | Lin Elizabeth Yeu | Chief Medical Officer | Open market sale | 1,590 | $80.00 |
| 2026-09-01 | Lin Elizabeth Yeu | Chief Medical Officer | Open market sale | 4,601 | $73.86 |
| 2026-06-17 | Azamian Bobak R. | President/CEO and Board Chair | Open market sale | 4,582 | $61.24 |
| 2026-06-17 | Azamian Bobak R. | President/CEO and Board Chair | Open market sale | 5,418 | $61.81 |
| 2026-06-16 | Farrow Jeffrey S | See Remarks | Open market sale | 14,396 | $60.95 |
| 2026-06-15 | Farrow Jeffrey S | See Remarks | Option exercise | 27,881 | — |
| 2026-06-15 | Goodrich Katherine | Director | Open market sale | 2,954 | $62.08 |
| 2026-06-15 | LINK WILLIAM J PHD | Director | Open market sale | 10,572 | $61.97 |
| 2026-06-15 | LINK WILLIAM J PHD | Director | Open market sale | 1,928 | $62.94 |
| 2026-06-12 | Morrison Scott W | Director | Option exercise | 2,954 | — |
| 2026-06-12 | LINK WILLIAM J PHD | Director | Option exercise | 2,954 | — |
| 2026-06-12 | CHAUDHURI BHASKAR | Director | Option exercise | 2,954 | — |
| 2026-06-12 | Goodrich Katherine | Director | Option exercise | 2,954 | — |
| 2026-06-12 | YARNO WENDY L | Director | Option exercise | 2,954 | — |
| 2026-06-12 | Goldberg Andrew D. | Director | Option exercise | 2,954 | — |
| 2026-04-24 | PYOTT DAVID E I | Director | Option exercise | 1,383 | — |
| 2026-03-20 | Neervannan Seshadri | Chief Operating Officer | Open market sale | 2,989 | $66.75 |
| 2026-03-19 | Whitfield Dianne C. | Chief Human Resources Officer | Open market sale | 4,174 | $67.00 |
| 2026-03-19 | Wahl Bryan | General Counsel | Open market sale | 4,231 | $67.00 |
| 2026-03-19 | Neervannan Seshadri | Chief Operating Officer | Open market sale | 4,589 | $67.00 |
| 2026-03-19 | Mottiwala Aziz | Chief Commercial Officer | Open market sale | 4,440 | $67.00 |
| 2026-03-18 | Whitfield Dianne C. | Chief Human Resources Officer | Open market sale | 4,071 | $68.71 |
| 2026-03-18 | Wahl Bryan | General Counsel | Open market sale | 4,125 | $68.71 |
| 2026-03-18 | Neervannan Seshadri | Chief Operating Officer | Open market sale | 3,610 | $68.71 |
| 2026-03-18 | Mottiwala Aziz | Chief Commercial Officer | Open market sale | 4,330 | $68.71 |
| 2026-03-17 | Whitfield Dianne C. | Chief Human Resources Officer | Open market sale | 4,029 | $69.42 |
| 2026-03-17 | Wahl Bryan | General Counsel | Open market sale | 4,084 | $69.42 |
| 2026-03-17 | Neervannan Seshadri | Chief Operating Officer | Open market sale | 3,125 | $69.42 |
| 2026-03-17 | Mottiwala Aziz | Chief Commercial Officer | Open market sale | 4,286 | $69.42 |
Recent SEC filings
Official company reports and insider transaction filings. Form 4 reports a transaction; it does not by itself explain why it happened.
Source: SEC EDGAR submissions · updated 2026-09-07 16:23 UTC
| Filed | Form | Report period | Official filing |
|---|---|---|---|
| 2026-09-03 | 4 | 2026-09-02 | View on SEC.gov → |
| 2026-09-03 | 4 | 2026-09-01 | View on SEC.gov → |
| 2026-08-06 | 10-Q | 2026-06-30 | View on SEC.gov → |
| 2026-08-06 | 8-K | 2026-08-06 | View on SEC.gov → |
| 2026-08-06 | 8-K | 2026-08-05 | View on SEC.gov → |
| 2026-08-06 | 8-K | 2026-07-31 | View on SEC.gov → |
| 2026-07-13 | 8-K | 2026-07-13 | View on SEC.gov → |
| 2026-07-08 | 8-K | 2026-07-06 | View on SEC.gov → |
| 2026-06-29 | 4 | 2026-06-25 | View on SEC.gov → |
| 2026-06-29 | 4 | 2026-06-25 | View on SEC.gov → |
| 2026-06-29 | 4 | 2026-06-25 | View on SEC.gov → |
| 2026-06-29 | 4 | 2026-06-25 | View on SEC.gov → |
Recent news
Headlines about TARS (Tarsus Pharmaceuticals, Inc.). Links open the publisher — we don’t host full articles.
-
Tarsus Pharmaceuticals CEO Bobak R. Azamian Offloads 10,000 Shares at $80.06 Each (NASDAQ: TARS)
Kalkine Media · 2026-09-04 -
Officer at Tarsus (NASDAQ: TARS) lines up six-figure stock sale
Stock Titan · 2026-09-04 -
Tarsus Stock Jumps 9%; Alkeus Upfront Package Is Now Worth $536 Million
TechStock² · 2026-09-04 -
After recent sales, Tarsus (NASDAQ: TARS) officer's spouse plans another stock trade
Stock Titan · 2026-09-04 -
About $943K in stock set for sale at Tarsus (TARS)
Stock Titan · 2026-09-04 -
Planned Tarsus (TARS) officer sale covers 4,564 shares
Stock Titan · 2026-09-04 -
Tarsus Pharmaceuticals Shares Rise After Closing Alkeus Pharmaceuticals Acquisition
marketscreener.com · 2026-09-04 -
Tarsus Pharmaceuticals stock hits all-time high at 85.29 USD
Investing.com · 2026-09-04
No headlines in this category right now — try “All”.